A carregar...
EGFR TKI as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer
After the discovery of activating mutations in EGFR, EGFR tyrosine kinase inhibitors (TKIs) have been introduced into the first-line treatment of non-small-cell lung cancer (NSCLC). A series of studies have shown that EGFR TKI monotherapy as first-line treatment can benefit NSCLC patients harbouring...
Na minha lista:
| Publicado no: | Oncotarget |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Impact Journals LLC
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5650459/ https://ncbi.nlm.nih.gov/pubmed/29088904 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.20095 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|